Ratings Xlife Sciences AG

Equities

XLS

CH0461929603

Market Closed - Swiss Exchange Other stock markets 11:30:31 2024-05-16 EDT			5-day change	1st Jan Change
34.3 ^CHF	-3.11%		-2.83%	-31.26%

04-23	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
02-29	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
XLIFE SCIENCES AG	-31.26%	224M	-
MODERNA, INC.	+33.61%	49.46B	B-
IQVIA HOLDINGS INC.	+1.76%	42.58B	B
LONZA GROUP AG	+49.11%	42.49B	A
CELLTRION, INC.	-4.22%	29.09B	C
ICON PUBLIC LIMITED COMPANY	+11.66%	26.61B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.64B	B
BIO-TECHNE CORPORATION	+7.85%	13.16B	B+
MEDPACE HOLDINGS, INC.	+29.52%	12.55B	C+
UNITED THERAPEUTICS CORPORATION	+23.70%	12.1B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes